The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Tyrosinemia: A Review
Abstract
Hypertyrosinemia encompasses several entities, of which tyrosinemia type I (or hepatorenal tyrosinemia, HT1) results in the most extensive clinical and pathological manifestations involving mainly the liver, kidney, and peripheral nerves. The clinical findings range from a severe hepatopathy of early infancy to chronic liver disease and rickets in the older child; gradual refinements in the diagnosis and medical management of this disorder have greatly altered its natural course, mirroring recent advances in the field of metabolic diseases in the past quarter century. Hepatorenal tyrosinemia is the inborn error with the highest incidence of progression to hepatocellular carcinoma, likely due to profound mutagenic effects and influences on the cell cycle by accumulated metabolites. The appropriate follow-up of patients with cirrhosis, the proper timing of liver transplantation in the prevention of carcinoma, and the long-term evolution of chronic renal disease remain important unresolved issues. The introduction of a new pharmacologic agent, NTBC, holds the hope of significantly alleviating some of the burdens of this disease. Mouse models of this disease have permitted the exploration of newer treatment modalities, such as gene therapy by viral vectors, including ex vivo and in utero methods. Finally, recent observations on spontaneous genetic reversion of the mutation in HT1 livers challenge conventional concepts in human genetics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
On the enzymic defects in hereditary tyrosinemia.
Lindblad, B., Lindstedt, S., & Steen, G. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.10.4641 · Cited by 447
Grompe, M., al-Dhalimy, M., Finegold, M., Ou, C. N., Burlingame, T., Kennaway, N. G., & Soriano, P. (1993) · Genes & Development · doi:10.1101/gad.7.12a.2298 · Cited by 355 · cited 1×
“A targeted deletion of the FAH gene was produced by Grompe et al. [ 67 ], the FAH homozygotes dying shortly after birth from fulminant liver failure, with a phenotype similar to the “acute” form of tyrosinemia in humans.”
MethodGrompe, M., Lindstedt, S., Al-Dhalimy, M., Kennaway, N. G., Papaconstantinou, J., Torres-Ramos, C. A., Ou, C.-N., & Finegold, M. (1995) · Nature Genetics · doi:10.1038/ng0895-453 · Cited by 312
The occurrence of hepatoma in the chronic form of hereditary tyrosinemia
Weinberg, A. G., Mize, C. E., & Worthen, H. G. (1976) · The Journal of Pediatrics · doi:10.1016/s0022-3476(76)80259-4 · Cited by 283
Tyrosinaemia type I and NTBC (2‐(2‐nitro‐4‐trifluoromethylbenzoyl)‐1,3‐cyclohexanedione)
Holme, E., & Lindstedt, S. (1998) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1005410820201 · Cited by 264
Gluecksohn-Waelsch, S. (1979) · Cell · doi:10.1016/0092-8674(79)90001-1 · Cited by 218 · cited 1×
“The “lethal albino” mouse was first described in 1979 [ 65 ], resulting from a large deletion on mouse chromosome 7, spanning both the albino and the FAH genes.”
Self-induced correction of the genetic defect in tyrosinemia type I.
Kvittingen, E. A., Rootwelt, H., Berger, R., & Brandtzaeg, P. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117509 · Cited by 168
Grompe, M., St.-Louis, M., Demers, S. I., Al-Dhalimy, M., Leclerc, B., & Tanguay, R. M. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408113310603 · Cited by 135 · cited 2×
“Bergman AJ, van den Berg IE, Brink W, Poll-The BT, Ploos van Amstel JK, Berger R. Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries.”
Self-citationPhaneuf, D., Lambert, M., Laframboise, R., Mitchell, G., Lettre, F., & Tanguay, R. M. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115979 · Cited by 84
Self-citationBerger, R., Van Faassen, H., Taanman, J. W., De Vries, H., & Agsteribbe, E. (1987) · Pediatric Research · doi:10.1203/00006450-198710000-00005 · Cited by 37
Cited by
A laser-engraved wearable sensor for sensitive detection of uric acid and tyrosine in sweat
Yang, Y., Song, Y., Bo, X., Min, J., Pak, O. S., Zhu, L., Wang, M., Tu, J., Kogan, A., Zhang, H., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-019-0321-x · Cited by 1,270
Wearable and flexible electrochemical sensors for sweat analysis: a review
Gao, F., Liu, C., Zhang, L., Liu, T., Wang, Z., Song, Z., Cai, H., Fang, Z., Chen, J., Wang, J., et al. (2023) · Microsystems & Nanoengineering · doi:10.1038/s41378-022-00443-6 · Cited by 764
Skin-Interfaced Wearable Sweat Sensors for Precision Medicine
Min, J., Tu, J., Xu, C., Lukas, H., Shin, S., Yang, Y., Solomon, S. A., Mukasa, D., & Gao, W. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00823 · Cited by 712
Tyrosine biosynthesis, metabolism, and catabolism in plants
Schenck, C. A., & Maeda, H. A. (2018) · Phytochemistry · doi:10.1016/j.phytochem.2018.02.003 · Cited by 286
Disorders of Tyrosine Metabolism
Chakrapani, A., & Holme, E. (2006) · Inborn Metabolic Diseases · doi:10.1007/978-3-540-28785-8_18 · Cited by 52
Cardiomyopathy in tyrosinaemia type I is common but usually benign
Arora, N., Stumper, O., Wright, J., Kelly, D. A., & McKiernan, P. J. (2006) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-006-0203-5 · Cited by 48
“The underlying defect is a mutation in the gene for fumarylacetoacetase (FAA) (EC 3.7.1.2), the last step in tyrosine degradation ( Russo et al 2001 ).”
BackgroundInfluentialOrejuela, D., Jorquera, R., Bergeron, A., Finegold, M. J., & Tanguay, R. M. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.09.014 · Cited by 34
Self-citationLectin‐reactive α‐Fetoprotein in Patients with Tyrosinemia Type I and Hepatocellular Carcinoma
Baumann, U., Duhme, V., Auth, M. K. H., McKiernan, P. J., & Holme, E. (2006) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/01.mpg.0000228112.29359.f8 · Cited by 25
“276700) is a multisystem disorder of tyrosine degradation with a heterogeneous phenotype of its liver disease ranging from acute liver failure in the newborn period to cirrhosis and hepatocellular carcinoma (HCC) in teenage years (1,2).”
BackgroundSchlump, J. ‐., Perot, C., Ketteler, K., Schiff, M., Mayatepek, E., Wendel, U., & Spiekerkoetter, U. (2008) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-008-0807-z · Cited by 24
Plasma succinylacetone is persistently raised after liver transplantation in tyrosinaemia type 1
Bartlett, D. C., Preece, M. A., Holme, E., Lloyd, C., Newsome, P. N., & McKiernan, P. J. (2013) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-012-9482-1 · Cited by 21
Recomendaciones y manejo de la tirosinemia hereditaria Tipo I o Tirosinemia hepatorrenal
Couce, M. L., Aldámiz-Echevarría, L., Baldellou, A., Blasco, J., Bueno, M. A., Dalmau, J., De La Vega, A., Del Toro, M., Díaz, C., Lama, R., et al. (2010) · Anales de Pediatría · doi:10.1016/j.anpedi.2010.03.005 · Cited by 15
Schlump, J.-U., Mayatepek, E., & Spiekerkoetter, U. (2010) · European Journal of Pediatrics · doi:10.1007/s00431-009-1074-1 · Cited by 13
Metadata
- Authors
- Russo, P. A., Mitchell, G. A., & Tanguay, R. M.
- Venue
- Pediatric and Developmental Pathology
- Publisher
- SAGE Publications
- Published
- 2001-05
- Volume
- 4
- Issue
- 3
- Pages
- 212-221
- ISSN
- 1093-5266 (ISSN-L)
- 1615-5742
- OpenAlex
- W1967607849
- Cited by
- 220
- References
- 10
- FWCI
- 1.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.